Online citations, reference lists, and bibliographies.
← Back to Search

A Double-blind, Placebo-controlled, Crossover Study Of Osmotic Release Oral System Methylphenidate In Adults With ADHD With Assessment Of Oppositional And Emotional Dimensions Of The Disorder.

F. Reimherr, E. Williams, R. Strong, R. Mestas, Poonam Soni, B. Marchant
Published 2007 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND The realization that attention-deficit/hyperactivity disorder (ADHD) often persists into adulthood has led to increased frequency of diagnosis and treatment in adults. Osmotic release oral system (OROS) methylpheni-date is a long-acting stimulant demonstrated to be effective in the treatment of children and adolescents with ADHD. METHOD Forty-seven adults entered and 41 completed this double-blind, placebo-controlled, crossover trial of OROS methylphenidate. Each double-blind arm lasted 4 weeks; data were collected from August 2004 through December 2005. Subjects met both DSM-IV-TR and Utah Criteria for ADHD in adults. Outcome measures included the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), the adult ADHD-Rating Scale (ADHD-RS), and the Clinical Global Impressions-Improvement scale (CGI-I). At baseline, subjects were categorized as having significant emotional symptoms with the WRAADDS and/or significant oppositional-defiant symptoms using a self-report scale assessing the DSM-IV criteria for oppositional defiant disorder. RESULTS 17% of the sample (N = 8) had ADHD alone, 38% (N = 18) had ADHD plus significant emotional symptoms, and 40% (N = 19) had ADHD with both significant emotional and oppositional symptoms. At a mean +/- SD dose of 64.0 +/- 23.3 (0.75 mg/kg), OROS methylphenidate proved superior to placebo for all clinical measures: total WRAADDS score decrease of 42% versus 13%, respectively, p < .001 and total ADHD-RS score decrease of 41% versus 14%, respectively, p = .003, plus the subscales addressing inattention, hyperactivity/ impulsivity, and emotional dysregulation. CONCLUSIONS OROS methylphenidate proved effective in treating adult ADHD. ADHD alone was relatively uncommon. Over 80% of our patients had ADHD with a combination of emotional and/or oppositional symptoms.



This paper is referenced by
10.1007/978-3-319-56015-1_319-1
Efficacy of Amphetamines, Methylphenidate, and Modafinil in the Treatment of Mental Disorders
W. Retz (2021)
10.21203/rs.3.rs-710647/v1
Emotional Dysregulation And Quality of Life In Young Adults With ADHD- A Cross Sectional Study
Maayan Ben Dor Cohen (2021)
10.1186/s40479-021-00162-w
Borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD) revisited – a review-update on common grounds and subtle distinctions
Ismene Ditrich (2021)
10.4088/jcp.19m13077
Types of Adult Attention-Deficit/Hyperactivity Disorder: A Replication Analysis.
F. Reimherr (2020)
10.1371/journal.pone.0240584
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis
Jesse Elliott (2020)
10.1192/j.eurpsy.2019.11
Toward operationalizing deficient emotional self-regulation in newly referred adults with ADHD: A receiver operator characteristic curve analysis
J. Biederman (2020)
10.1007/978-3-030-39051-8_3
The Phenotypic Expression of ADHD in Adulthood
S. Pallanti (2020)
Investigation in the overlap of ADHD and borderline personality disorder : a multi-modal approach
T. R. Moukhtarian (2019)
10.1177/1087054719883022
Resting-State fMRI Study of ADHD and Internet Gaming Disorder
D. Han (2019)
School and Work Experiences of Adults with ADHD: A Qualitative Case Study
Julieta E. Robello (2019)
10.1080/14656566.2019.1618270
Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD)
G. Perugi (2019)
Emotional Intelligence in Attention Deficit Hyperactivity Disorder
Yapça Kaypaklı (2018)
10.1177/1087054717719534
The Impact of Emotional Lability Symptoms During Childhood in Adults With ADHD
Laura Gisbert (2018)
10.1016/j.neubiorev.2017.08.010
Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis
F. Lenzi (2018)
10.5350/dajpn2018310101
Effects of methylphenidate treatment on quality of life in adolescents
Canan Kuygun Karcı (2018)
10.1007/978-3-319-64251-2_11
Moody Adults with ADHD
Michael J Silverstein (2018)
10.1177/1087054718756198
Validation of the Expanded Versions of the Adult ADHD Self-Report Scale v1.1 Symptom Checklist and the Adult ADHD Investigator Symptom Rating Scale
Michael J Silverstein (2018)
10.3310/PGFAR06020
Crossing the divide: a longitudinal study of effective treatments for people with autism and attention deficit hyperactivity disorder across the lifespan
D. Murphy (2018)
10.2147/NDT.S164807
Six months methylphenidate treatment improves emotion dysregulation in adolescents with attention deficit/hyperactivity disorder: a prospective study
Ipek Suzer Gamli (2018)
10.18863/PGY.358101
Dikkat Eksikliği ve Hiperaktivite Bozukluğunda Duygu Düzenleme Güçlükleri ve Tedavisi
Y. Öztürk (2018)
10.1177/1087054718780323
The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD
Laura Gisbert (2018)
10.1007/s40263-018-0503-y
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
T. Wigal (2018)
The Effects of Childhood Irritability on Adolescent Outcomes and Treatment Response in Children with Attention-Deficit/Hyperactivity Disorder
Estrella Heber (2017)
10.1007/978-3-319-39794-8_6
ADHD and Bipolar Disorder
J. Sadek (2017)
10.1007/s11695-017-3037-3
Emotion Self-Regulation Moderates the Association Between Symptoms of ADHD and Weight Loss After Bariatric Surgery
T. Williamson (2017)
10.1177/1087054716688251
Emotional Intelligence as an Evolutive Factor on Adult With ADHD
J. Quintero (2017)
10.1002/jclp.22317
Emotional Dysregulation in Adults With Attention-Deficit/Hyperactivity Disorder-Validity, Predictability, Severity, and Comorbidity.
Salvatore Corbisiero (2017)
10.1177/1087054717690808
Psychometric Properties and Factor Structure of the Short Form of the Affective Lability Scale in Adult Patients With ADHD
S. Weibel (2017)
10.1016/j.eurpsy.2017.05.021
Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis
T. R. Moukhtarian (2017)
10.3949/ccjm.84a.15051
ADHD: Overdiagnosed and overtreated, or misdiagnosed and mistreated?
M. Manos (2017)
10.1016/S2215-0366(16)30032-3
Adult attention-deficit hyperactivity disorder: key conceptual issues.
P. Asherson (2016)
Attention-defi cit hyperactivity disorder 2 Adult attention-defi cit hyperactivity disorder: key conceptual issues
P. Asherson (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar